ReviewCureus2025
Pulsed-Field Ablation for Paroxysmal Atrial Fibrillation: Current Evidence and Its Potential Role as First-Line Therapy.
Review in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Pulsed field ablation versus thermal ablation for paroxysmal atrial fibrillation: a systematic review and meta-analysis.International journal of cardiology. Heart & vasculature · 2026Article
- Efficacy and safety of pulsed field ablation for cavotricuspid isthmus-dependent atrial flutter: A meta-analysis based on real-world evidence.Heart rhythm O2 · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pulsed-field ablation (PFA) is a novel, non-thermal energy modality that specifically targets the myocardium by using irreversible electroporation. This review summarizes the available data regarding the effectiveness, safety, and procedural time for PFA versus traditional thermal ablation for paroxysmal atrial fibrillation. While recent trials have shown that PFA results in outcomes comparable to those of radiofrequency ablation and cryoablation for rhythm control, they have also demonstrated a significant reduction in collateral damage to surrounding structures such as the esophagus and phrenic nerve. Faster procedure times, along with a more favorable safety profile for PFA, could offer advantages for patients and health care providers. Since preliminary evidence indicates PFA may be used safely and effectively as a first-line ablation therapy for AF, additional long-term data and larger-scale real-world analyses are needed to evaluate PFA's longevity and establish its role in routine clinical use. Overall, PFA offers a new direction for the development of catheter-based rhythm control therapies that are faster, safer, and more efficient than previously available options for atrial fibrillation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.